Compare BGMS & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGMS | TCRT |
|---|---|---|
| Founded | 1996 | 1998 |
| Country | Malaysia | United States |
| Employees | 19 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9M | 4.7M |
| IPO Year | N/A | 2025 |
| Metric | BGMS | TCRT |
|---|---|---|
| Price | $0.92 | $1.94 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 106.7K | 13.6K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 24.66 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,900,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $80,482.35 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.57 | $1.67 |
| 52 Week High | $6.70 | $4.57 |
| Indicator | BGMS | TCRT |
|---|---|---|
| Relative Strength Index (RSI) | 52.05 | 32.32 |
| Support Level | $0.89 | N/A |
| Resistance Level | $1.13 | $3.10 |
| Average True Range (ATR) | 0.08 | 0.10 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 49.21 | 0.00 |
Bio Green Med Solution Inc is engaged in the supply and trading of protective and fire safety equipment. The company distributes products such as fire extinguishers, foam systems, fire-resistant doors, personal protective equipment, and safety apparel. It also provides fire safety systems, including sprinkler systems, fire alarm systems, valves, and CO2 systems. The company operates across commercial, industrial, healthcare, and residential sectors, with a focus on distribution and compliance with applicable safety standards.
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.